168 related articles for article (PubMed ID: 37444014)
1. E-Cadherin Immunostaining in Equine Melanocytic Tumors.
Pimenta J; Pires I; Prada J; Cotovio M
Animals (Basel); 2023 Jul; 13(13):. PubMed ID: 37444014
[TBL] [Abstract][Full Text] [Related]
2. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors.
Pimenta J; Prada J; Pires I; Cotovio M
Vet Sci; 2024 Feb; 11(2):. PubMed ID: 38393095
[TBL] [Abstract][Full Text] [Related]
4. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis.
Silvestri S; Porcellato I; Mechelli L; Menchetti L; Iussich S; De Maria R; Sforna M; Bongiovanni L; Brachelente C
Vet Pathol; 2020 Sep; 57(5):608-619. PubMed ID: 32578507
[TBL] [Abstract][Full Text] [Related]
5. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
6. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
[TBL] [Abstract][Full Text] [Related]
8. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
Sanders DS; Blessing K; Hassan GA; Bruton R; Marsden JR; Jankowski J
Mol Pathol; 1999 Jun; 52(3):151-7. PubMed ID: 10621837
[TBL] [Abstract][Full Text] [Related]
9. Cadherin expression in melanocytic naevi and malignant melanomas.
Cowley GP; Smith ME
J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
[TBL] [Abstract][Full Text] [Related]
10. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
Seleit IA; Samaka RM; Basha MA; Bakry OA
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors.
Pimenta J; Prada J; Pires I; Cotovio M
Animals (Basel); 2023 Dec; 14(1):. PubMed ID: 38200779
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
13. Shifts in cadherin profiles between human normal melanocytes and melanomas.
Hsu MY; Wheelock MJ; Johnson KR; Herlyn M
J Investig Dermatol Symp Proc; 1996 Apr; 1(2):188-94. PubMed ID: 9627715
[TBL] [Abstract][Full Text] [Related]
14. The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors.
Bozhkova DM; Poryazova-Markova EG
Folia Med (Plovdiv); 2019 Jun; 61(2):296-302. PubMed ID: 31301662
[TBL] [Abstract][Full Text] [Related]
15. Melanocytic Ophthalmic Neoplasms of the Domestic Veterinary Species: A Review.
Wang AL; Kern T
Top Companion Anim Med; 2015 Dec; 30(4):148-57. PubMed ID: 27154598
[TBL] [Abstract][Full Text] [Related]
16. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tyrosinase expression in canine and equine melanocytic tumors.
Phillips JC; Lembcke LM; Noltenius CE; Newman SJ; Blackford JT; Grosenbaugh DA; Leard AT
Am J Vet Res; 2012 Feb; 73(2):272-8. PubMed ID: 22280389
[TBL] [Abstract][Full Text] [Related]
18. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).
Valentine BA
J Vet Intern Med; 1995; 9(5):291-7. PubMed ID: 8531173
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.
Roesch A; Becker B; Meyer S; Wild P; Hafner C; Landthaler M; Vogt T
Mod Pathol; 2005 Sep; 18(9):1249-57. PubMed ID: 15803180
[TBL] [Abstract][Full Text] [Related]
20. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
